InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,729.74
(
-0.15%
)
US TECH 100
19,402.00
(
-0.35%
)
Dow Jones
42,130.38
(
-0.43%
)
Brent Oil
71.90
(
0.27%
)
Bitcoin
63,332.49
(
-3.50%
)
Post# of 253255
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120512
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 71387

Friday, 02/06/2009 8:05:17 AM

Friday, February 06, 2009 8:05:17 AM

Post# of 253255
IDIX 2009 Clinical Goals

[Updated for IDX899 partnership with GSK.]


HCV

1Q09: Start IDX184 phase-2a combination study (SoC ± IDX184). (The phase-1/2 monotherapy trial, which started in late December, is a prerequisite: #msg-34763865.)

1Q09/2Q09: Report data from phase-1/2 IDX184 monotherapy study. This could come at EASL or perhaps sooner (the treatment period is only three days).

April 2009: Report preliminary results of IDX184 phase-2a study at EASL.

1H09: File IND for IDX375 non-nucleoside polymerase inhibitor.

1H09: File IND for IDX136 and IDX316 protease inhibitors.


HIV

1H09: Start IDX899 head-to-head trial vs Sustiva (IDX899+Truvada vs Sustiva+Truvada in first- and second-line patients). Note: this trial will be run by IDIX’s partner, GSK.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up